Monday, October 26, 2026

Back to today

How to Read a 10-K Like a Short Seller

A four-layer 10-K framework tests revenue timing, receivables, reserves and depreciation against cash flow, using Hertz’s 2012-14 accounting as a case study.

From X

@StableBread 1 click

Fajasy on X

Boost Run $BRUN said on October 26 that it has closed "more than $600 million in non-dilutive project financing" so far in 2026. In my October 19 update, I said the stock depends less on demand than on whether $BRUN can finance the next ~$1B of GPUs without selling shares at beaten-down prices. The release also says: → $BRUN has established "a fully funded runway to accelerate customer deployments through the fourth quarter of 2026," with additional financing "proceeding as planned." → $BRUN delivered the first phase of a multi-phase project to "a leading AI research and product company," which matches its $471.7M May 2026 contract with Thinking Machines Lab (Mira Murati's AI startup). → Several more projects are "nearing hand-off in the coming weeks." → Founder and CEO Andrew Karos: "Customer payments exceed our debt payments every month." The $600M+ is YTD, and lessors funded $268.3M of new GPU leases in H1 2026 alone. So if those leases count toward the $600M+, $BRUN has closed more than $331.7M since June 30, about half to almost two-thirds of the $527-686M of new leases I estimated its H2 2026 build needs. The release doesn't say what the financing costs or how much of it closed since June 30. However, the Q3 10-Q, expected in mid-November, should disclose how much $BRUN leased in Q3 and at what rate. If the 10-Q confirms the $600M+, I'd drop the $62.2M stock sale from my bear case, and the question shifts from whether $BRUN can fund its build to what the new debt costs.

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

ADCT · long

Adc Therapeutics SA (adct)

ADC Therapeutics centers on ZYNLONTA, an approved CD19-directed antibody-drug conjugate, after shares rose from roughly $4.

Portillo’s: Strategic Reset

Portillo’s reset follows weak Texas unit economics, cutting next year’s openings to five from roughly 10 annually and shrinking store…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.